Results 81 to 90 of about 8,117 (271)

Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments

Med Research, EarlyView.
ABSTRACT The immune microenvironment includes immune cells, cytokines, extracellular matrix, vesicles, etc. The interactions between these components form a unique local immune microecology. Although immunity serves as the defense against external pathogens, aberrant immune activation often contributes to disease development.
Guoqing Li, Yuxuan Wan, Alan Jiao, Ke Jiang, Gaoyuan Cui, Jinxin Tang, Simin Yu, Zhengang Hu, Songfeng Zhao, Zhenjie Yi, Lifu Long, Yang Yang, Xuehao Cui, Chunrun Qu   +13 more
wiley   +1 more source

Benralizumab in Real Life [PDF]

Journal of Investigational Allergology and Clinical Immunology, 2021
J.C. Miralles López, A.I. Escudero Pastor, C. Navarro Garrido, Y. Bonilla Pacheco, Y Petrik Petrik, A. Carbonell Martínez   +5 more
openaire   +2 more sources

Benralizumab for PDGFRA -Negative Hypereosinophilic Syndrome

New England Journal of Medicine, 2019
Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a monoclonal antibody against interleukin-5 receptor α, which is expressed on human eosinophils.In this randomized, double-blind, placebo-controlled, phase 2 trial, we administered a series ...
Michael P. Fay, JeanAnne Ware, Jamie H. Ellis, Roland Kolbeck, Li Yan, Xiaoping Sun, Tamika Magee, Fanny Legrand, Lauren Wetzler, Astin Powers, Michelle Makiya, Hawwa Alao, Sandhya R. Panch, Paul Newbold, Brent Piligian, Irina Maric, Paneez Khoury, Amy D. Klion, Mitchell Goldman, Martha Quezado, Nancy Raitano Lee, Tom Brown, Pryscilla Yoon, Fei Li Kuang, Sheila Kumar   +24 more
openaire   +3 more sources

A prospective study exploring the predictors of response to benralizumab in patients with refractory bronchial asthma

Fujita Medical Journal, 2022
Objective: This study aimed to evaluate the predictors of response to benralizumab therapy in patients with refractory bronchial asthma. Methods: After 16 weeks of benralizumab therapy, 32 patients with refractory bronchial asthma were assigned to two
Masahiro Hirose, Kazunobu Kuwabara, Rieko Kondo, Takahiko Horiguchi   +3 more
doaj   +1 more source

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma

, 2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Katsaounou, Paraskevi, Martinez, Rafael, Pfister, Pascal, Wahn, Ulrich   +6 more
core   +1 more source

Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score

Allergy, EarlyView.
A retrospective cohort of newly diagnosed treatment‐naive patients with ABPA in Japan who were followed up for up to 3 years after the primary diagnosis was analyzed to explore the clinical remission rate and clinical characteristics of ABPA resistant to standard treatment or prone to exacerbation during/after treatment.
Jun Tanaka, Tsuyoshi Oguma, Takashi Ishiguro, Hirokazu Taniguchi, Teruaki Nishiuma, Hiroki Tateno, Hisako Matsumoto, Naoki Koshimizu, Yutaka Ito, Kazuto Matsunaga, Hidekazu Matsushima, Yoshitaka Uchida, Koshi Yokomura, Hirotaka Yasuba, Junko Suzuki, Shigeaki Hattori, Naoki Okada, Katsuyoshi Tomomatsu, Koichiro Asano, on behalf of ABPM Research Program   +19 more
wiley   +1 more source

Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma

Allergy, EarlyView.
This study analyzed the clinical and biomarker data from 175 adults with severe asthma treated with the anti‐TSLP monoclonal antibody tezepelumab. Following tezepelumab initiation, the exacerbation rate decreased, with 59% of patients remaining exacerbation‐free at 1 year. Asthma symptom control as measured by ACQ‐6 significantly improved after 4 weeks
Jessica Gates, Faizan Haris, Francesca Cefaloni, Paniz Khooshemehri, Linda Green, Mariana Fernandes, Louise Thomson, Cris Roxas, Jodie Lam, Grainne d'Ancona, Alexandra M. Nanzer, Jaideep Dhariwal, David J. Jackson   +12 more
wiley   +1 more source

Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. [PDF]

, 2020
Background: The humanized monoclonal antibody benralizumab targets the α subunit of the interleukin-5 (IL-5) receptor and the FcγRIIIa receptor expressed by natural killer cells.
Alessandro Vatrella, Claudia Crimi, Corrado Pelaia, Giovanna Elisiana Carpagnano, Girolamo Pelaia, Maria Teresa Busceti, Nicola Lombardo, Rosa Terracciano   +7 more
core   +1 more source

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj  

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection

Respirology Case Reports, 2021
Chronic eosinophilic pneumonia (CEP) is a rare disorder characterized by marked accumulation of eosinophils in lung tissues and/or bronchoalveolar lavage fluid (BALF). Patients with CEP usually respond well to corticosteroids.
Tomotsugu Takano, Yuh Inutsuka, Satoshi Nakamura, Nobuhisa Ando, Masashi Komori   +4 more
doaj   +1 more source